“Cervical Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cervical Cancer Market.

The Cervical Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cervical Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cervical Cancer treatment therapies with a considerable amount of success over the years.

• Cervical Cancer companies working in the treatment market are Rubius Therapeutics, Nurix, PDS Biotechnology Corporation, Vaccibody AS, Roche, EMD Serono, Eli Lilly and Company, AkesoBiopharma, Regeneron Pharmaceuticals, and others, are developing therapies for the Cervical Cancer treatment

• Emerging Cervical Cancer therapies such as – RTX 321, DeTIL 0255, PDS 0101, VB10.16, Tiragolumab, Bintrafusp alfa, Gemcitabine, Cadonilimab, Cemiplimab, and others are expected to have a significant impact on the Cervical Cancer market in the coming years.

• In July 2025, Tisotumab vedotin (Tivdak), an innovative antibody-drug conjugate (ADC), marks a notable advancement in the treatment of recurrent cervical cancer. This tissue factor-targeting therapy signifies a shift in the current treatment landscape, offering better outcomes in progression-free and overall survival compared to traditional chemotherapy. The study reported an increase in response rates from 5% to 17%. However, experts note that while these results are encouraging, the survival benefits—1.5 months in progression-free survival and 2 months in overall survival—remain modest, underscoring the need for continued progress in cervical cancer treatment.

• In March 2025, According to results from the second interim analysis of the Phase 3 KEYNOTE-A18 trial (NCT04221945), presented at the 2025 SGO Annual Meeting on Women’s Cancer, the combination of pembrolizumab (Keytruda) with chemoradiotherapy, followed by pembrolizumab alone, significantly and/or meaningfully improved overall survival (OS) and time to second disease progression or death (PFS2). It also demonstrated a sustained progression-free survival (PFS) advantage compared to chemoradiotherapy alone in patients with newly diagnosed, high-risk, stage IB2 to IIB, node-positive, or stage III to IVA locally advanced cervical cancer.

• In May 2025, The FDA awarded fast track designation to ADRX-0706, a Nectin-4-targeting antibody-drug conjugate (ADC), for treating advanced cervical cancer. This designation aims to speed up the development and review of treatments that fulfill urgent medical needs for serious diseases.

• In December 2024, The FDA granted fast track designation to CRB-701, a Nectin-4–targeting antibody-drug conjugate (ADC), for the potential treatment of adults with relapsed/refractory metastatic cervical cancer. CRB-701 is a next-generation ADC that incorporates a site-specific, cleavable linker, a uniform drug-to-antibody ratio of 2, and a novel monoclonal antibody targeting Nectin-4. It was designed to overcome the dose-limiting toxicities associated with the linker-payload system used in enfortumab vedotin-efjv (Padcev).

• In March 2024, Merck (MSD) has announced that the Phase III KEYNOTE-A18 (ENGOT-cx11/GOG-3047) clinical trial of Keytruda combined with chemoradiotherapy (CRT) in cervical cancer patients has achieved its primary endpoint. This double-blind, randomized trial is being conducted by MSD in collaboration with the European Network for Gynecological Oncology Trial (ENGOT) groups and the GOG Foundation.

Cervical Cancer Overview

Cervical cancer is a type of cancer that develops in the lower part of the uterus, known as the cervix. It usually begins with abnormal cell changes that grow uncontrollably and can spread to nearby tissues if not treated early.

Get a Free Sample PDF Report to know more about Cervical Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight

Emerging Cervical Cancer Drugs Under Different Phases of Clinical Development Include:

• RTX 321: Rubius Therapeutics

• DeTIL 0255: Nurix

• PDS 0101: PDS Biotechnology Corporation

• VB10.16: Vaccibody AS

• Axalimogene filolisbac: Advaxis

• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.

• Tiragolumab: Roche

• AK104: Akeso

• Bintrafusp alfa: EMD Serono

• Durvalumab: AstraZeneca

• Gemcitabine: Eli Lilly and Company

• HLX10: Shanghai Henlius Biotech

• Cadonilimab: AkesoBiopharma

• Cemiplimab: Regeneron Pharmaceuticals

Route of Administration

Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Cervical Cancer Pipeline Therapeutics Assessment

• Cervical Cancer Assessment by Product Type

• Cervical Cancer By Stage and Product Type

• Cervical Cancer Assessment by Route of Administration

• Cervical Cancer By Stage and Route of Administration

• Cervical Cancer Assessment by Molecule Type

• Cervical Cancer by Stage and Molecule Type

DelveInsight’s Cervical Cancer Report covers around 70+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cervical Cancer product details are provided in the report. Download the Cervical Cancer pipeline report to learn more about the emerging Cervical Cancer therapies

Some of the key companies in the Cervical Cancer Therapeutics Market include:

Key companies developing therapies for Cervical Cancer are – Regeneron Pharmaceuticals, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA, Seagen Inc., Vaccibody AS, Qilu Pharmaceutical Co., Ltd., Genor Biopharma Co., Ltd., Roche, Guangzhou Gloria Biosciences Co., Ltd., Lee’s Pharmaceutical Limited, BeiGene, Henlix Biotech, Biocad, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Cellid Co., Ltd., Innovent Biologics, Zeria Pharmaceutical, Advaxis, Inc., Hookipa Biotech GmbH, GlaxoSmithKline, Iovance Biotherapeutics, Inc., NETRIS Pharma, Rubius Therapeutics, Repertoire Immune Medicines, SOTIO Biotech a.s., VM Oncology, LLC, Andes Biotechnologies, Transgene, Xencor, Inc., Exelixis, Ocellaris Pharma, Inc, Fate Therapeutics, Arcus Biosciences, In., MacroGenics, and others.

Cervical Cancer Pipeline Analysis:

The Cervical Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cervical Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cervical Cancer Treatment.

• Cervical Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cervical Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cervical Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cervical Cancer drugs and therapies

Cervical Cancer Pipeline Market Drivers

• Increase in the incidence of oncological disease, large number of ongoing clinical trials are some of the important factors that are fueling the Cervical Cancer Market.

Cervical Cancer Pipeline Market Barriers

• However, high cost of therapy, side-effects associated and other factors are creating obstacles in the Cervical Cancer Market growth.

Scope of Cervical Cancer Pipeline Drug Insight

• Coverage: Global

• Key Cervical Cancer Companies: Rubius Therapeutics, Nurix, PDS Biotechnology Corporation, Vaccibody AS, Roche, EMD Serono, Eli Lilly and Company, AkesoBiopharma, Regeneron Pharmaceuticals, and others

• Key Cervical Cancer Therapies: RTX 321, DeTIL 0255, PDS 0101, VB10.16, Tiragolumab, Bintrafusp alfa, Gemcitabine, Cadonilimab, Cemiplimab, and others

• Cervical Cancer Therapeutic Assessment: Cervical Cancer current marketed and Cervical Cancer emerging therapies

• Cervical Cancer Market Dynamics: Cervical Cancer market drivers and Cervical Cancer market barriers

Request for Sample PDF Report for Cervical Cancer Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/